Priadel remains on market after price negotiations
- PDF / 169,313 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 10 Downloads / 202 Views
1
Priadel remains on market after price negotiations Essential Pharma’s lithium formulation, Priadel, which is used for the treatment of bipolar disorders, is to remain on the market in the UK following price negotiations between the manufacturer and the Department for Health and Social Care (DHSC), reports Elisabeth Mahase in the BMJ. After Essential Pharma previously announced it would withdraw Priadel in April 2021, the Competition and Markets Authority (CMA) launched an investigation into whether the manufacturer was withdrawing the drug in order that patients would be switched to more expensive treatments such as Essential Pharma’s other lithium formulation, Camcolit. The company has now struck a deal with the DHSC; Priadel will be supplied at £7.50 and £8.50 per pack of 200mg and 400mg tablets, respectively. The cost of Camcolit is £48.18 for a pack of 400mg tablets. "These proposed commitments would last for five years and include continuing to supply Priadel on terms agreed with the DHSC. It would mean that the company cannot threaten to withdraw Priadel in order to increase the price without good reason," said the CMA. The CMA is continuing the investigation into whether competition law was broken, and is seeking views from invited stakeholders. "We will carefully consider any responses to the consultation before reaching our final decision, with the best protection for patients in mind," said Ann Pope, CMA senior director of antitrust. Mahase E. Priadel: bipolar drug will remain on market after new price is agreed by government. BMJ : 25 Nov 2020. Available from: URL: https://www.bmj.com/ content/371/bmj.m4603
1173-5503/20/0868-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803519987
PharmacoEconomics & Outcomes News 12 Dec 2020 No. 868
Data Loading...
